Antibodies bearing the T15 idiotype dominate the murine primary immune response to phosphocholine (PC). Analysis of antigen binding of antibodies derived from V1:DFL16.1:JH1 (VH1) germline and N region-derived variant heavy (H) chains and kappa 22, kappa 24, and kappa 8 light (L) chains demonstrates that the T15H:kappa 22L (T15) antibody binds PC at least 20-40 times better than other antibodies derived from alternate germline forms of the VH1 H chain and kappa 22, kappa 24, or kappa 8 L chains. To achieve affinities in the same range as the T15 antibody, kappa 24 and kappa 8 L chain-containing antibodies must have H chains derived from variant N region or somatically mutated VH1 genes. Single amino acid differences at the VD junction of the various germline and N region variant VH1 H chains dictate the L chain that can associate with the H chain to produce a PC-specific antibody. Several H:L combinations give rise to T15 or M167 idiotype-positive antibodies that lack specificity for PC, and single amino acid substitutions or insertions at the VH1:D junction result in the loss of T15 or M167 idiotopes. Based on these observations, our data support a molecular model involving both preferential gene rearrangement and antigen-driven B cell selection to explain T15 idiotype dominance in the immune response to PC. In the absence of N region diversification, large numbers of neonatal B cells bearing the T15H:kappa 22L surface immunoglobulin M (sIgM) receptors would be selected and expanded by autologous or environmental PC antigen into the long-lived peripheral B cell pool.
Skip Nav Destination
Article navigation
1 December 1992
Article|
December 01 1992
Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance.
J J Kenny,
J J Kenny
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
C M Moratz,
C M Moratz
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
G Guelde,
G Guelde
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
C D O'Connell,
C D O'Connell
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
J George,
J George
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
C Dell,
C Dell
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
S J Penner,
S J Penner
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
J S Weber,
J S Weber
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
J Berry,
J Berry
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
J L Claflin
J L Claflin
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Search for other works by this author on:
J J Kenny
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
C M Moratz
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
G Guelde
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
C D O'Connell
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
J George
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
C Dell
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
S J Penner
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
J S Weber
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
J Berry
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
J L Claflin
Program Resources, Inc/DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1992) 176 (6): 1637–1643.
Citation
J J Kenny, C M Moratz, G Guelde, C D O'Connell, J George, C Dell, S J Penner, J S Weber, J Berry, J L Claflin; Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance.. J Exp Med 1 December 1992; 176 (6): 1637–1643. doi: https://doi.org/10.1084/jem.176.6.1637
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement